Fig 1: Aurora A inhibitor, alisertib reduces the invasive properties of basal B breast cancer cells. (a) Concentration-dependent inhibition of cell viability performed in basal B cells to determine the IC50 of Aurora A inhibitor alisertib, as assessed by an MTT assay 72 h after treatment; (b) Western blot analysis of Aurora A, Bcl-xL and vimentin in MDA-MB-468, CAL-120 and MDA-MB-231 cells before and after treatment with alisertib (10 µM in MDA-MB-468 cells and 20 µM in CAL-120 and MDA-MDA-MB-231 cells, treated for 72 h). GAPDH was used as loading control; (c) Analysis of invasion properties of basal A and basal B cells treated with alisertib (10 µM in MDA-MB-468 cells and 20 µM in CAL-120 and MDA-MB-231 cells, treated for 72 h) relative to cells without chemoattractant. The data represent the mean of two biological replicates ± SEM.
Fig 2: Basal B TNBC cells exhibit amplification of AURKA and BCL2L1 and overexpression of Aurora A and Bcl-xL. (a) Evaluation of AURKA and BCL2L1 gene copy numbers by quantitative RT-PCR copy number assay using TaqMan copy number variant (CNV) primers in basal A or B breast cancer cell lines. RNase P was used as reference. The data represent the mean of three biological replicates ± SEM. Statistically significant differences calculated by one-way ANOVA are shown as ns > 0.05, ** p = 0.01, *** p = 0.001 and **** p = 0.0001; (b) Western blot analysis of Aurora A and Bcl-xL in lysates from MDA-MB-468, CAL-120 and MDA-MB-231 cell lines. GAPDH was used as loading control. A representative of 2 biological replicates is shown; (c) Immunocytochemical analysis of FFPE basal A, MDA-MB-468 cells and basal B, CAL-120 and MDA-MB-231 cell lines, stained for Aurora A and Bcl-xL (×20).
Fig 3: Inhibition of Aurora A with alisertib and blockage of Bcl-xL reduces invasion of basal B breast cancer cells. A schematic presentation showing the role of Aurora A and Bcl-xL in regulating basal B cell growth and metastatic capability (created with BioRender.com, Toronto, ON, Canada).
Fig 4: High AURKA and BCL2L1 expression correlates with shorter relapse-free survival (RFS) and distant metastasis-free survival (DMFS) in TNBC. Kaplan–Meier survival curves of RFS and DMFS for (a) BCL2L1 and (b) AURKA mRNA expression by KM plotter analysis; (c) Kaplan–Meier survival curves of RFS ad DMFS for combined BCL2L1 and AURKA mRNA expression by KM plotter analysis.
Supplier Page from MilliporeSigma for Anti-AURKA antibody produced in rabbit